A team of researchers has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings may help improve future ways to deliver ...

As lead candidate mipletamig continues to outperform efficacy and safety benchmarks in AML trials, APVO711 exemplifies emerging innovation from Aptevo's proprietary ADAPTIR® platformIn preclinical stu ...

Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA) Phase 3 ARCHER II Trial ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients ...

Legend Biotech faces a 60% stock drop amid safety, supply issues, and competition for its CAR-T therapy, Carvykti. See here ...

GeoVax Labs ( GeoVax Labs Stock Quote, Chart, News, Analysts, Financials NSQ:GOVX) received a “Buy” rating and a $18.00 ...

Immunocore Holdings' stock has dropped 60% as Kimmtrak faces market saturation, but its pipeline could offer potential. Find ...

"Year to date" sales for 2021, 2022, 2023, and 2024 sales are shown in series at the top of the table and then just below a comparison of 2024 versus 2023 and 2024 versus 2022 is displayed. This ...

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission ...

Following the Pahalgam terror attack, which resulted in 28 fatalities, Pakistan's leadership is convening a National Security Committee meeting to formulate a ...